The OncLive® Sponsored section encompasses all sponsored content that is presented as articles, video interviews, webinars, blog posts, and more across various types of malignancies, including breast cancer, lung cancer, hematologic cancers, gynecologic cancers, gastrointestinal cancers, genitourinary cancers, and more.
November 18th 2021
This content was developed in collaboration with Servier Pharmaceuticals and Onc Live
August 25th 2021
Adaptive Biotechnologies OncLive Sponsored Content Q&A
August 11th 2021
Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death
July 15th 2021
Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
June 14th 2021
June 9th 2021
Sponsored Content by Adaptive Biotechnologies
June 7th 2021
Sponsored Content by Tempus
April 26th 2021
Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
March 31st 2021
Sponsored Content by Ipsen
March 30th 2021
Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.
December 16th 2020
Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
October 20th 2020
As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.